...S*BIO has links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. More information about S*BIO can be found at www.sbio.com. Onyx Pharmaceuticals,...

...has also been pretty deft with "at-risk" launches itself. As a result, it recently announced that it'll launch generic versions of Novartis' Femara. More than 94% of 455 CAPS members rating Mylan see the company beating the S&P going forward. ViroPharma Not...

...Sanof Aventis. Then there is Chiron Panacea Vaccines, the 50:50 joint venture between Indian vaccine major Panacea Biotech and Novartis (which acquired Chiron), which will launch its own hexa-vaccine targeting the same six diseases, say industry experts. YK...

...industries. MicroDose's partnered programs include; multi-product development and licensing agreements with Merck and Co. and Novartis, the development of an inhaled insulin product through MicroDose's QDose joint venture, and an inhaler for the systemic...

... At this point, you may be in the mood for the more predictable performance of such dividend payers as McDonald's (NYSE: MCD) or Novartis (NYSE: NVS). But let's see if we can't play devil's advocate. First, Nordic did not cast the proceeds from its share offerings...

...Additional members of the FORMA founding team include: Steven Tregay, Ph.D., President and CEO, formerly Managing Director, Novartis Option Fund; and Nikolai Kley, Ph.D., Vice President of Biology and Head of Drug Discovery, formerly Vice President and Head...

...companies that are doing amazing things that meet real needs, which can save large companies a lot of money. Merck, Pfizer, and Novartis is sending clear signals: they're asking us to find companies for them, and we're working on six deals in Israel." "The...

...other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy,...

...follow-on drugs, copycat versions of biologic drugs, are already marketed in Europe. Big pharmaceutical companies like Merck (MRK) and Novartis (NVS) are in the business. Genentech's McCracken says biosimilars will be in the U.S. market in the foreseeable...

...modified crops that are jumping on the band wagon stealing and selling and altering all the products available from Eli Lilly Novartis Glaxo Smitt Kline and all others and coming up with their own creations occasionally. But they are all the same to me drug...